Vaishali Pharma Reports Nil Deviation in Utilization of Preferential Issue Proceeds
Vaishali Pharma Ltd · Others (Uncategorized) · 15 Nov 2026, 1:15 am
Vaishali Pharma Reports Nil Deviation in Utilization of Preferential Issue Proceeds Vaishali Pharma Limited confirmed zero deviation or variation under Regulation 32 of SEBI Listing Regulations for the quarter ended 30th Sep'26. The company fully utilized the entire preferential issue proceeds of ₹9,07,57,300 raised on 3rd Jul'26 via share swap. The funds were deployed entirely toward part-funding the acquisition of equity shares in Kesar Pharma Limited to expand its pharmaceutical product portfolio, realize strategic synergies, and enhance shareholder value. The Audit Committee and Board reviewed and approved the statement on 14th Nov'26 without adverse remarks.
Original exchange filing (PDF)
More announcements from Vaishali Pharma Ltd
- Vaishali Pharma Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. · 15 Nov 2026
- Vaishali Pharma Limited has informed the Exchange about Board Meeting to be held on 14-Nov-2026 to consider and approve the Quarterly Unaudited Financial results of the Company for the period ended September 2026 and Other business. · 14 Nov 2026
- To consider and approve the financial results for the period ended September 30, 2026 and other business matters · 14 Nov 2026
- Vaishali Pharma Limited has informed the Exchange regarding Appointment of Mr. Rohil Sanjay Desai and Mr. Ketur Kishor Shah as Non- Executive Independent Director of the company w.e.f. November 05, 2026. · 06 Nov 2026
- Vaishali Pharma Limited has informed the Exchange regarding Outcome of Board Meeting held on November 05, 2026. · 06 Nov 2026
- Vaishali Pharma Limited has informed the Exchange about Board Meeting to be held on 05-Nov-2026 to consider and approve Other business/Increase in authorised capital/Fund raising. · 03 Nov 2026
- To consider Fund Raising and other business matters · 03 Nov 2026
- Vaishali Pharma Limited has informed the Exchange about General Updates · 17 Oct 2026
